# reload+after+2024-01-23 12:37:59.205709
address1§6 Heddon Street
city§London
zip§W1B 4BT
country§United Kingdom
website§https://genflowbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
fullTimeEmployees§5
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Eric Jean Leire M.D., MBA', 'age': 65, 'title': 'Founder, CEO & Executive Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 235432, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Cedric  Szpirer', 'title': 'Head of CMC', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
priceToSalesTrailing12Months§24.869453
currency§GBp
exchange§LSE
quoteType§EQUITY
shortName§GENFLOW BIOSCIENCES PLC ORD GBP
longName§Genflow Biosciences plc
firstTradeDateEpochUtc§1642406400
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§c2b066c2-f4f8-3276-9986-e6d0cd9e7fce
recommendationKey§none
quickRatio§9.712
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
